Category: Press releases
Genome sequencing of thousands of patients with rare blood disorders
Approximately 3M people have a rare bleeding disorder or disease of platelets, which are the cell fragments that help blood clot.
Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma …
Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.
Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic…
Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.
The root of evil: pre-leukemic clones that survive chemotherapy are linked to a …
Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission.
Stopping tyrosine kinase inhibitors in a very large cohort of European chronic …
Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.
Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab
Hodgkin Lymphoma typically affects young men and women in their 30s.
A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT…
A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER! We recently discovered a new form of an inherited deficiency of platelets (inherited thrombocytopenia-IT), which is…
EHA Award winners put in the spotlight in Copenhagen
Copenhagen, June 9 2016. At the 21st Congress of the European Hematology Association (EHA) in Copenhagen, in total thirteen hematology researchers will be awarded for their work. Research is the engine that drives improvements in patient care which is why EHA is keen in investing in Awards and Grants to stimulate and support hematology research.
PRESS RELEASE: The future of research in hematology is here
The Hague, January 27, 2016 In the February 2016 issue of Haematologica, critical research of blood and blood-forming organs in Europe is given a boost. The European Hematology Association Roadmap for European Hematology Research: A Consensus Document summarizes the current status of basic, translational and clinical hematology research and identifies areas of unmet scientific and medical need in Europe. It provides guidance for European and national policy makers, funding agencies, charities, research institutes and researchers when they make decisions on initiating or funding research and developing research programs.
A new targeted combination therapy with potential to eliminate relapsed chronic …
Vienna, June 12, 2015 – Promising results from an early phase trial combining the anti-bcl-2 drug Venetoclax with Rituximab to eliminate CLL are presented by Dr Andrew Roberts.
Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresis…
Vienna, June 12, 2015 –Dr Guryanova will present a new mechanism for chemoresistance in AML based on acquired DNA mutations.
New GFI1B variants in bleeding and platelet disorders
Vienna, June 12, 2015 –Dr Marneth will discuss the findings of eight new genetic variants in GFI1B that have been discovered in patients with bleeding and platelet disorders and consequences for new therapeutic targets.
Does the patient with myelofibrosis feel better through Pacritinib?
Vienna, June 12, 2015 –Dr Mesa will present new data from the phase 3 PERSIST-1 study on improving disease symptoms and quality of life for patients with myelofibrosis.
First randomized evidence for kinase inhibitor activity in acute myeloid leukemi…
Vienna, June 12, 2015 – Dr Ehninger will present the results of a phase II randomized study on the safety and efficacy of Sorafenib.
The European Union must deliver funding for research of blood disorders
At the Congress of the European Hematology Association (EHA) – attracting 10,000 hematologists from Europe and beyond - the president of EHA, Prof. Christine Chomienne, called upon the European Union to deliver funding for Research into Blood Disorders:
“The hematologists in Europe have done a great work. Now it’s the EU’s turn to deliver.”